New drug duo targets rare abdominal cancer in phase 2 trial
NCT ID NCT07328425
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests a combination of two chemotherapy drugs, lurbinectedin and irinotecan, in 20 people with advanced desmoplastic small round cell tumor (DSRCT) that cannot be removed by surgery. The goal is to shrink or control the tumor and track side effects. An optional part of the study looks at the tumor's genes to learn more about how it behaves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, MI, 20133, Italy
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.